NCT02875821View on ClinicalTrials.gov

Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 26, 2016

Primary Completion Date

June 7, 2017

Study Completion Date

June 7, 2017

Conditions
Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)
Interventions
DRUG

Ipragliflozin

Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)

DRUG

metformin with pioglitazone

Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)

Trial Locations (1)

03722

Yonsei University College of Medicine, Department of internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02875821 - Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone | Biotech Hunter | Biotech Hunter